Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-03 · accession 0001209191-24-000929 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-04 | 2024-01-03 | VKTX | ZANTE GREG | CFO | A - Grant | $0.00 | +98.3K | 188.7K | +109% | $0 |
| D | 2024-01-04 | 2024-01-04 | VKTX | ZANTE GREG | CFO | S - Sale | $17.90 | -15.0K | 180.7K | -8% | -$268.5K |
| DM | 2024-01-04 | 2024-01-03+ | VKTX | ZANTE GREG | CFO | F - Tax | $17.66 | -63.0K | 209.6K | -23% | -$1.11M |
| D | 2024-01-04 | 2024-01-03 | VKTX | ZANTE GREG | CFO | A - Grant | $0.00 | +155.0K | 155.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2024-01-03 | A | A | 70,000 | $0.00 | 240,491 | D | — | — | (F4) Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. |
| 2 | Common | Common Stock, par value $0.00001 per share | 2024-01-04 | S | D | 15,000 | $17.90 | 180,730 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock, par value $0.00001 per share | 2024-01-04 | F | D | 13,872 | $18.58 | 195,730 | D | — | — | (F5) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. |
| 4 | Common | Common Stock, par value $0.00001 per share | 2024-01-03 | A | A | 28,334 | $0.00 | 188,724 | D | — | — | (F1) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal. (F2) Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. |
| 5 | Common | Common Stock, par value $0.00001 per share | 2024-01-03 | F | D | 18,233 | $17.40 | 170,491 | D | — | — | (F3) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. |
| 6 | Common | Common Stock, par value $0.00001 per share | 2024-01-03 | F | D | 30,889 | $17.40 | 209,602 | D | — | — | (F5) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-01-03 | A | A | 155,000 | $0.00 | 155,000 | D | $17.40 · 2025-01-03 to 2034-01-03 | 155,000 Common Stock | (F7) 25% of the shares subject to the option will vest on each anniversary of the grant date. |